

Resource Summary Report

Generated by [nidm-terms](#) on Jul 29, 2026

SynergyFinder

RRID:SCR_019318

Type: Tool

Proper Citation

SynergyFinder (RRID:SCR_019318)

Resource Information

URL: <https://bioconductor.org/packages/synergyfinder/>

Proper Citation: SynergyFinder (RRID:SCR_019318)

Description: Software R package as efficient implementations for all popular synergy scoring models for drug combinations, including HSA, Loewe, Bliss and ZIP and visualization of synergy scores as either two dimensional or three dimensional interaction surface over dose matrix. Used to calculate and visualize synergy scores for drug combinations.

Synonyms: synergyfinder

Resource Type: software application, software resource, data processing software, data visualization software, software toolkit

Defining Citation: [DOI:10.1007/978-1-4939-7493-1_17](https://doi.org/10.1007/978-1-4939-7493-1_17)

Keywords: Synergy scores, drug combinations, popular synergy scoring models, dimensional interaction surface, dose matrix, bio.tools

Availability: Free, Available for download, Freely available

Resource Name: SynergyFinder

Resource ID: SCR_019318

Alternate IDs: biotools:synergyfinder

Alternate URLs: <https://bio.tools/synergyfinder>

Record Creation Time: 20220129T080344+0000

Record Last Update: 20260729T044501+0000

Ratings and Alerts

No rating or validation information has been found for SynergyFinder.

No alerts have been found for SynergyFinder.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 510 mentions in open access literature.

Listed below are recent publications. The full list is available at [nidm-terms](#).

Higuchi M, et al. (2026) FSP1 and histone deacetylases suppress cancer persister cell ferroptosis. *Science advances*, 12(1), eaea8771.

Zeng B, et al. (2026) An organolutetium nanosensitizer synergizes with PARP inhibition to unleash STING-mediated immunity for low-dose radioimmunotherapy. *Theranostics*, 16(4), 1720.

Makhmut A, et al. (2026) Spatial proteomics of ovarian cancer precursors delineates early disease changes and drug targets. *Molecular systems biology*, 22(1), 7.

Li JJ, et al. (2026) NSD2 targeting reverses plasticity and drug resistance in prostate cancer. *Nature*, 649(8095), 216.

Mansoori S, et al. (2026) Characterization of the anticancer effect of mebendazole and its interaction with standard cytotoxic drugs in patient tumor cells ex vivo and in an in vivo mouse model. *Oncology reports*, 55(1).

Stern YE, et al. (2026) Targeting CDK12/13 Drives Mitotic Arrest to Overcome Resistance to KRASG12C Inhibitors. *Cancer research*, 86(2), 485.

Jameson NM, et al. (2025) The Selective WEE1 Inhibitor Azenosertib Shows Synergistic Antitumor Activity with KRASG12C Inhibitors in Preclinical Models. *Cancer research communications*, 5(2), 240.

Huang C, et al. (2025) Targeting p38 γ synergistically enhances sorafenib-induced cytotoxicity in hepatocellular carcinoma. *Cell biology and toxicology*, 41(1), 35.

Pan M, et al. (2025) Bone morphogenetic protein (BMP) signaling determines neuroblastoma cell fate and sensitivity to retinoic acid. *Nature communications*, 16(1), 2036.

Chan SPY, et al. (2025) Functional combinatorial precision medicine for predicting and optimizing soft tissue sarcoma treatments. *NPJ precision oncology*, 9(1), 83.

Lu C, et al. (2025) Combined targeting of glioblastoma stem cells of different cellular states disrupts malignant progression. *Nature communications*, 16(1), 2974.

Kaldjob-Heinrich L, et al. (2025) Adenosine Receptor 3 in Liver Cancer: Expression Variability, Epigenetic Modulation, and Enhanced Histone Deacetylase Inhibitor Effects. *Gastro hep advances*, 4(3), 100590.

Panda PK, et al. (2025) BCL-XL Protects ASS1-Deficient Cancers from Arginine Starvation-Induced Apoptosis. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(7), 1333.

Yang J, et al. (2025) Discovery of YJZ5118: A Potent and Highly Selective Irreversible CDK12/13 Inhibitor with Synergistic Effects in Combination with Akt Inhibition. *Journal of medicinal chemistry*, 68(6), 6718.

Tarantelli C, et al. (2025) KAT/3BP: A Metabolism-Targeting Agent with Single and Combination Activity in Aggressive B-Cell Lymphomas. *Cancers*, 17(12).

Harfoot R, et al. (2025) Synthetic host defense peptide inhibits SARS-CoV-2 replication in vitro. *Antimicrobial agents and chemotherapy*, 69(8), e0170024.

Nath S, et al. (2025) Unlocking the therapeutic potential of rigosertib as a selective therapy for ovarian cancer. *Cell reports. Medicine*, 6(7), 102218.

Qin X, et al. (2025) Paclitaxel-induced mitotic arrest results in a convergence of apoptotic dependencies that can be safely exploited by BCL-XL degradation to overcome cancer chemoresistance. *bioRxiv : the preprint server for biology*.

Liu H, et al. (2025) Anlotinib enhances the efficacy of KRAS-G12C inhibitors through c-Myc/ORC2 axis inhibition in non-small cell lung cancer. *Cell death & disease*, 16(1), 356.

Tang H, et al. (2025) Ciprofloxacin enhances RSL3-induced ferroptosis by promoting mitochondrial Zn²⁺ accumulation via the STING1-CAV2 pathway. *The Journal of biological chemistry*, 301(10), 110653.